A Repeated Dose Study of KHK6640 in Japanese Patients With Alzheimer's Disease

Exclusion Criteria

• •Previous active treatment with an Alzheimer's Disease immunotherapy in an investigational study
• •Use of another investigational drug within 16 weeks prior to the enrollment
• •Subjects who meet National Institute of Neurological Disorders and Stroke/Association Internationale pour la Recherche et l'Enseignement en Neurosciences (NINDS/AIREN) criteria for vascular dementia
• •Subjects with a history of presence of clinically significant seizures, brain trauma, transient ischemic attack, and/or cerebrovascular disease
• •Subjects with a presence of a neurological condition that could be contributing to cognitive impairment above and beyond that caused by the subject's Alzheimer's Disease
• •Subjects who have evidence of infection, tumor, or other clinically significant lesions that could indicate a dementia diagnosis other than Alzheimer's Disease